Denosumab biosimilar - Shandong Boan Biotechnology

Drug Profile

Denosumab biosimilar - Shandong Boan Biotechnology

Alternative Names: LY 06006

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shandong Boan Biotechnology
  • Developer Luye Pharma Group; Shandong Boan Biotechnology
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Postmenopausal osteoporosis

Most Recent Events

  • 04 Aug 2017 Luye Pharma Group acquires denosumab biosimilar from Shandong Bo’an Biotechnology
  • 04 Aug 2017 Preclinical trials in Postmenopausal osteoporosis in China (Parenteral) before August 2017
  • 04 Aug 2017 Denosumab biosimilar receives approval to conduct clinical trials in China prior to August 2017 (9221464; 3265709)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top